Curium Nears $7B Lantheus Buyout at $114.50/Share
LNTH has more than doubled off its 52-week low of $47.25.
Summary
Curium is reportedly close to acquiring Lantheus for about $7 billion, offering roughly $102 per share upfront plus an additional $12.50 per share. The total consideration of $114.50 represents a modest premium to the current $106.7 price. This follows a recent FDA Complete Response Letter for LNTH-2501, which may have pressured the stock and created an opportunistic entry for the buyer. The deal would combine two major players in radiopharmaceuticals, potentially reshaping the competitive landscape. No prior acquisition talks were disclosed in the timeline, making this a fresh, market-moving event. Investors will watch for official confirmation and any regulatory hurdles given the sector's consolidation.
At the time of this announcement, LNTH was trading at $106.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. The 52-week trading range was $47.25 to $111.86. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.